An observational study in Benign Prostatic Hyperplasia, sponsored by Saint Vincent's Hospital, Korea. Recruiting at 1 site in Korea, Republic of. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2024-11-06.
Sponsored by Saint Vincent's Hospital, Korea · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Prostatic Hyperplasia with a site in Korea, Republic of — 6 open to participants now, 6 under way, none of them phase 3. Prostatic Hyperplasia · Korea, Republic of.
Among the 72 studies in Prostatic Hyperplasia with a site in Korea, Republic of, this one is the 8th largest by planned enrollment of the 15 observational ones that give a count, is one of 3 that started in 2023, is one of 15 observational ones, and was the 65th registered.
828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.
Browse Prostatic Hyperplasia studies →6 of the 72 studies in Prostatic Hyperplasia with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Addpharma Inc. · Sites in Korea, Republic of
Ages 19+ · Men only · Healthy volunteers
Société Internationale d'Urologie · Sites in Korea, Republic of, United States, Canada and 18 more countries
Ages 18+ · Men only
AJU Pharm Co., Ltd. · Sites in Korea, Republic of
Ages 19–54 · Men only · Healthy volunteers
Addpharma Inc. · Sites in Korea, Republic of
Ages 19+ · Men only · Healthy volunteers
Addpharma Inc. · Sites in Korea, Republic of
Ages 19+ · Men only · Healthy volunteers
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 50 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 250 across 177 observational studies indexed under Prostatic Hyperplasia.
Median enrollment 83 across the 57 interventional studies, 300 across the 15 observational. Of the 54 that completed or were terminated, 8 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 72 have an industry lead sponsor. The 10 most frequent:
Saint Vincent's Hospital, Korea is the lead sponsor of 20 studies on the registry; 8 are open to participants now.
Saint Vincent's Hospital, Korea has 1 study filed under Prostatic Hyperplasia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 72 studies in Prostatic Hyperplasia with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn about the efficacy of Rezum water vapor thermal therapy in benign prostatic hyperplasia patients. The main question it aims to answer is:
Participants will be followed up for at least three months after the treatment to evaluate efficacy and safety.
This prospective cohort study aims to evaluate the safety and efficacy of the Rezum procedure, a minimally invasive treatment for benign prostatic hyperplasia (BPH) that utilizes convective water vapor thermal energy. The Rezum procedure was approved by the U.S. FDA in 2015, and recent approval by South Korea's Ministry of Health and Welfare has allowed its use in South Korean patients. Unlike other BPH treatments, Rezum delivers steam at 103°C directly into the prostatic tissue, inducing necrosis and reduction of prostate size through a controlled thermal effect. This process is conducted in a day-surgery setting under local, general, or spinal anesthesia, minimizing patient burden and recovery time.
The study will enroll male patients aged 50 or older with confirmed BPH who meet specific prostate size criteria, measured via transrectal ultrasound. Following a preoperative evaluation, including prostate size, PSA levels, symptom questionnaires, and urodynamic assessment, patients will undergo the Rezum procedure. This involves cystoscope-guided needle insertion into hypertrophic prostate regions, where targeted thermal energy is delivered in short bursts. The procedure is completed within a single hospital visit, and patients are generally discharged on the same day unless complications arise.
After surgery, participants will have routine follow-up visits, including catheter removal and initial voiding assessments within one week. Further follow-up, at a minimum of three months, will include standardized assessments of voiding function, symptom severity (IPSS, IIEF, OAB-q), prostate size, uroflowmetry, and residual urine volume. The safety profile will be assessed by recording adverse events, including infection, hematuria, voiding dysfunction, and the necessity for catheter reinsertion. Complications will be classified according to the Clavien-Dindo classification system.
Data analysis will assess the preoperative and postoperative changes in symptom severity, functional parameters, and prostate measurements. Comparisons of these continuous variables will utilize paired sample t-tests or Wilcoxon signed-rank tests, depending on normality test results. Variables include IPSS, IIEF, OAB-q, prostate size, PSA, maximum flow rate (Qmax), and post-void residual volume (PVR). Additionally, multiple regression analysis will identify factors contributing to the need for postoperative catheter reinsertion. Statistical significance will be set at α=0.05, with p-values below 0.05 indicating significant differences.
This study will address a current gap in research on the Rezum procedure's impact on Korean patients, contributing to the understanding of this minimally invasive approach within different populations and expanding its potential applicability.
The study subjects are patients requiring surgery for benign prostatic hyperplasia (BPH).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who underwent Rezum water vapor thermal therapy treatment for BPH
Procedure: Rezum (water vapor thermal therapy)
Rezum or water vapor thermal therapy is a procedure that involves injecting steam at 103°C into the prostate tissue to induce necrosis and reduce the size of the enlarged prostate.
International Prostate Symptom Score (IPSS)
International Prostate Symptom Score (IPSS) is a validated, reproducible scoring system to assess disease severity and response to therapy for BPH. The IPSS is made up of 7 questions related to voiding symptoms. A score of 0 to 7 indicates mild symptoms, 8 to 19 indicates moderate symptoms and 20 to 35 indicates severe symptoms.
Time frame: From enrollment to three months after treatment
Qmax
Maximal urine flow rate in uroflowmetry exam
Time frame: From enrollment to three months after treatment
Complications
Complications evaluated using the Clavien-Dindo classification
Time frame: Three months after treatment
Plan to share: Undecided — IPD will be shared upon reasonable request to the PI. The investigators do not have a specific URL to provide the information.
Started Jul 2023 (actual). Primary completion is estimated for Jul 2028, 60 months after the start.
Of 59 non-industry observational studies under Prostatic Hyperplasia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 50. This study's planned 60 months is above that.
Counting every sponsor, half of 74 studies reached it within 25 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Saint Vincent's Hospital, Korea